Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C66H81NO17 |
| Molecular Weight | 1160.3458 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 11 / 11 |
| E/Z Centers | 2 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]12C[C@H](O)[C@@]3(C)C(=O)[C@H](OC(C)=O)C4=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)C5=CC=CC=C5)[C@]3([H])[C@@]1(CO2)OC(C)=O)C4(C)C)OC(=O)[C@H](OC(=O)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC)[C@@H](NC(=O)C6=CC=CC=C6)C7=CC=CC=C7
InChI
InChIKey=FGSNWFZAHNIDKT-SEWYIPPUSA-N
InChI=1S/C66H81NO17/c1-8-9-10-11-12-13-14-15-16-17-18-19-20-21-31-38-51(71)81-62(76)82-55(53(45-32-25-22-26-33-45)67-59(73)46-34-27-23-28-35-46)61(75)80-48-40-66(77)58(83-60(74)47-36-29-24-30-37-47)56-64(7,49(70)39-50-65(56,41-78-50)84-44(4)69)57(72)54(79-43(3)68)52(42(48)2)63(66,5)6/h12-13,15-16,22-30,32-37,48-50,53-56,58,70,77H,8-11,14,17-21,31,38-41H2,1-7H3,(H,67,73)/b13-12-,16-15-/t48-,49-,50+,53-,54+,55+,56-,58-,64+,65-,66+/m0/s1
| Molecular Formula | C66H81NO17 |
| Molecular Weight | 1160.3458 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 10 / 11 |
| E/Z Centers | 2 |
| Optical Activity | UNSPECIFIED |
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:20:29 GMT 2023
by
admin
on
Fri Dec 15 15:20:29 GMT 2023
|
| Record UNII |
9C1VFB8B7X
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
76964551
Created by
admin on Fri Dec 15 15:20:29 GMT 2023 , Edited by admin on Fri Dec 15 15:20:29 GMT 2023
|
PRIMARY | |||
|
463952-62-7
Created by
admin on Fri Dec 15 15:20:29 GMT 2023 , Edited by admin on Fri Dec 15 15:20:29 GMT 2023
|
PRIMARY | |||
|
9C1VFB8B7X
Created by
admin on Fri Dec 15 15:20:29 GMT 2023 , Edited by admin on Fri Dec 15 15:20:29 GMT 2023
|
PRIMARY | |||
|
LOC-PAC
Created by
admin on Fri Dec 15 15:20:29 GMT 2023 , Edited by admin on Fri Dec 15 15:20:29 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
Phase I/II study of weekly LOC-paclitaxel (LOC-pac) injection in patients (pts) with metastatic melanoma (MM).
|
||
|
ACTIVE MOIETY |
Originator: Luitpold Pharmaceuticals; Developer: Luitpold Pharmaceuticals, University of Texas M. D. Anderson Cancer Center; Class: Antineoplastic, Diterpene, Paclitaxel, Small molecule, Taxane; Mechanism of Action: Mitosis inhibitor, Platelet-derived growth factor inhibitor, Proto-oncogene protein c-bcl-2 inhibitor, Tubulin inhibitor, Tubulin polymerisation promoter; Highest Development Phase: Phase I/II Malignant melanoma; Most Recent Event: 01 Feb 2016 Luitpold completes a phase I/II trial in Malignant melanoma (Metastatic disease) in USA (IV) (NCT01039844)
|
